Endocrine Research Updates

For Medical Professionals

Will weight loss or good blood sugar control improve type 2 diabetes.
Two leading experts debate the evidence and explore the benefits of initiating a blood glucose-directed or obesity-centric management treatment plan, pointing out the strengths in choosing one disease approach over the other.
A stepwise approach may improve detection of statin intolerance and better cholesterol-lowering management in patients who have had poor medication compliance despite their increased risk of both CVD and type 2 diabetes.
Patients with diabetes must be treated carefully to avoid common complications.
Expert panel addresses barriers to and advancements in achieving optimal hyperkalemia management aiming to improve outcomes regarding kidney disease and cardiovascular events in in patients with diabetes.
Study finds ticagrelor plus aspirin more effective in reducing ischemic cardiovascular events in patients with type 2 diabetes provided there is no heightened concern for excessive bleeding.
Hypertension is one of 5 key factors that indicate risk for metabolic syndrome.
Given the effectiveness of available interventions, the Endocrine Society issues a practice guideline to prompt proactive efforts at screening for the metabolic components leading to cardiovascular disease and type 2 Diabetes.
Malignancy of thyroid nodules can be informed by genetic variability.
Relying on molecular "rule-in" testing of thyroid nodules to better assess for cancer risk improves predictive value, based on a systematic review of the literature.
Older women at risk of bone loss should be treated cautiously with statins.
Benefit or detriment—New study raises potential adverse effects of statin therapy on bone health in patients with comorbid heart disease and osteoporosis. There are other complications necessitating specific considerations when prescribing statins in women at different ages and stages.
In seniors with diabetes, common disease complications respond well with SGLT2i
The latest study findings on the safety and efficacy of the SGLT-2i, ertugliflozin, offer strong assurance for use in managing diabetes in individuals at 65 years plus, and in others, without concerns for adverse effects on renal function.
Since up to 30% of patients with cancer experience insomnia, even years later, a team from Dana Farbar Cancer Institute has developed a stepwise approach to improve sleep and designed for ease of implementation in any practice setting.
Advances promise preservative-free, fast-acting inhaled insulin for diabetes.
Next Generation Soft-Mist Inhaled human Insulin and GLP-1RA are advancing for treatment of diabetes, and other hormone therapies are just beginning development.
Diabetes distress arises in patients overwhelmed with a chronic disease.
This often unrecognized response arises when individuals are overwhelmed when facing the responsibility of managing a chronic life-long disease. Thus, regular screening should become a routine aspect of diabetes patient care.
Heart failure and renal disease must be treated as a complication of diabetes.
Insights on FDA approvals, side effects of pain meds, and key study findings presented at the European Association for the Study of Diabetes annual meeting,
Patients with Cushing's disease should be monitored for diabetes.
Finally, a long-lasting, monthly injection of pasireotide promotes normalized urinary free cortisol levels and a shrinking or arresting of tumor growth in patients with Cushing’s disease.
GLP-1RAs offer excellent benefits for cardiovascular diabetes.
A new meta-analysis affirms improvements in cardiovascular, kidney and overall outcomes in patients given a GLP-1RA versus SGLT2i for management of type 2 diabetes. Even in those without established cardiovascular disease, significant benefits are achieved with glucagon-like peptide-1 receptor agonists.
Testosterone levels increase risk of nonalcoholic fatty liver disease.
Study findings suggest that elevated levels of androgens even in younger women may offer a clue to patients at increased risk of developing nonalcoholic fatty liver disease.
A new surgical procedure, a promising minimally invasive, endoscopic device, and new uses for established drugs offer relief from gastrointestinal symptoms of this common complication of diabetes
When prescribing a psych med, patients should be referred for weight loss.
Regardless of the type of psychiatric medications taken, including antidepressants and antipsychotics, patients who enroll in a weight loss program achieve weight loss, similar to those not taking these medications. This is important progress for many individuals who fear weight gain when they take psychopharmacological medications.
Thyroid hormones play a significant role in onset of NAFLD.
Type 2 diabetes is not the only precursor to nonalcoholic fatty liver disease, patients with thyroid disease also appear at elevated risk.
Parathyroid Hormone Treatment
The standard of care for hypoparathyroidism has been calcium and vitamin D replacement, making it the last endocrine deficiency for which hormone replacement is the treatment of choice.
The poor prognosis for aggressive thyroid tumors may improve with new drugs.
Considerable progress in understanding the molecular basis of rare thyroid cancer cases has led to the introduction of new drugs that target specific genetic mutations, enabling personalized care and improved survival.
close X